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Abstract
Background: Early vascular alteration, atherosclerosis and coronary artery disease have emerged as important
cardiovascular complications among beta-thalassemia major (B-TM) patients. The aims of the current study were to
assess the prevalence of premature atherosclerosis among our B-TM patients, and to investigate the diagnostic
value of serum Osteoprotegerin assay as an early biomarker for atherosclerosis.
Methods: This cross-sectional study was conducted at Hematology unit - Pediatric Department, Zagazig University
Children Hospital- Egypt in the period from March 2014 to March 2015. A total of 115 children were enrolled in the
current study; as sixty-five (65) children with beta thalassemia major aged 5–18 years, on regular blood transfusion
regimen represented the patient group. While fifty (50) healthy children, with comparable age and gender, were
assigned as control group. All participants were subjected to history taking, thorough clinical examination and
laboratory investigations including; complete blood count, liver and kidney function tests, C- reactive protein, lipid
profile, serum ferritin and serum Osteoprotegerin (OPG) assay. Also, carotid artery intima media thickness (CAIMT)
was performed by duplex ultrasound for patients and controls.
Results: Our B-TM patients were transfusion-dependent for as long as 8.5 ± 3.8 years with significantly higher serum
ferritin levels (2490 ± 1579 ng/dl vs 83 ± 32 ng/dl, p = 0.001), C-reactive protein (5.7 ± 5.7 vs 0.9 ± 0.9), liver enzymes
and bilirubin when compared to controls. Significantly higher serum triglyceride (128 ± 20 vs 101 ± 7 mg/dL, p = 0.
009) and atherogenic index of plasma (0.45 ± 0.12 vs 0.22 ± 0.04, p = 0.001) were recorded in patients than
comparisons. On the contrary, total serum cholesterol (116 ± 16 vs 143 ± 5, p < 0.001), low density lipoprotein-
cholesterol (LDL-C) (44 ± 9 vs 73 ± 6, p < 0.001) and high density lipoprotein cholesterol (HDL-C) (39 ± 2 vs 61 ± 5,
p < 0.001), were significantly lowered in patients versus normal peers. Carotid arteries intima media thickness (CAIMT)
of both side were significantly increased for patients (Rt 0.62 ± 0.2 vs. 0.29 ± 0.07 mm, p = 0.001 & Lt 0.66 ± 0.17 vs 0.29
± 0.05 mm, p = 0.001) when compared with healthy controls, and showed positive correlation with, serum triglyceride,
atherogenic index of plasma, and serum Osteoprotegerin levels. ELISA assay of serum Osteoprotegerin (OPG) revealed
significantly higher levels for thalassemia patients than matched healthy controls (427 ± 102 vs. 324 ± 126 pg/ml, p = 0.
02). Of particular interest is the obvious positive correlation between OPG levels and CAIMT of both sides
(Rt r 0.54, p = 0.001 &Lt r 0.479, p = 0.001) and also with serum triglycerides (r 0.374, p = 0.03).
(Continued on next page)
* Correspondence: Lamesh25@yahoo.com
1Pediatrics and Pediatric Hematology and Oncology, Faculty of Medicine,
Zagazig University, Zagazig, Egypt
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Sherief et al. BMC Pediatrics  (2017) 17:69 
DOI 10.1186/s12887-017-0820-1
(Continued from previous page)
Conclusions: Subclinical atherosclerosis started prematurely in children with beta- thalassemia. Carotid artery intima
media thickness represented a simple, accurate and non-invasivemodality for early detection ofatherosclerosis.
It was correlated well with serum Osteoprotegerin; this finding highlighted the possible validity of OPG assay as an
early predictor of atherosclerosis in thalassemia children.
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Background
Beta-thalassemia represents the commonest cause of
hemolytic anemia in Egypt with carrier rate ranges from 9–
10% [1]. Beta- thalassemia major (B-TM) patients usually
present within the first two years of life with severe anemia
requiring regular red blood cell transfusions [2]. Early vas-
cular alteration, atherosclerosis and coronary artery diseases
have emerged as important cardiovascular complications
among B-TM patients [3].
Atherosclerosis is a slow progressive disease that may
start at childhood [4]. In atherogensis, arterial wall morpho-
logical changes occur during a presumably long subclinical
lag phase, and characterized by gradual thickening of the
intima [5]. Beside the traditional diagnostic methods such
as angiography and stress-testing [6], measurement of the
intima-media thickness of the large arteries, especially the
carotids, has emerged as one of the method of choice for
determining the anatomical extent of arterial wall deterior-
ation and for assessing cardiovascular risk [5]. Several
investigators have recommended the clinical use of this
technique for detecting subclinical (asymptomatic) athero-
sclerosis and for identifying subjects at high-risk [7–9].
Circulating markers of atherosclerosis are associated with
increased vascular risk; one of the new biomarkers of ath-
erosclerosis is Osteoprotegerin (OPG) [10]. Osteoproteg-
erin is a cytokine of the tumor necrosis factor (TNF)
receptor superfamily and is classed as an osteoclastogenesis
inhibiting factor [11]. In the endothelial cell, OPG is associ-
ated with Von-Willebrand factor within secretory granules
called Weibel-Palade bodies. Upon stimulation with TNF
or interleukin-1 in vitro, the OPG- Von-Willebrand factor
complex is secreted in the surrounding growth medium.
This endothelial activation by pro-inflammatory cytokines
is one of the possible sources of circulating OPG in patients
with active atherosclerosis [12]. Moreover, in view of the
role of vascular smooth muscles in atherosclerosis and
intimal calcification, it is likely that, they are the main
source of increased circulating OPG noted in cardiovascu-
lar disease [13]. Data suggest that OPG is induced by
atherosclerosis and may be upregulated as an incomplete
compensatory response to the vessel insult, possibly thereby
limiting vascular calcification [14]. Osteoprotegerin seems
to prevent arterial calcification but is not able to reverse
calcification once it has occurred [15].
As the maximal potential for prevention and revers-
ibility of atherosclerosis would be expected by interven-
tion at early subclinical stage of the disease, its early
diagnosis in high-risk individuals should be a research
priority. The aims of the current work are; to assess the
frequency of premature subclinical atherosclerosis in
Egyptian B-TM patients by determining their carotid
artery intima-media thickness, to figure-out the associated
clinical and laboratory risk factors, and to evaluate the
validity of OPG assay as a new biomarker for early diagno-
sis of atherosclerosis in these high-risk population.
Methods
Patients
We carried out this cross-sectional, case–control study on
sixty –five (65) Beta-thalassemia major patients aged 5–18
years old. They were on regular follow-up at the Hematology
Unit of Pediatric Department, Zagazig University Children
Hospital- Egypt during the period from March 2014-March
2015. Fifty (50) apparently healthy children with comparable
age and gender distribution were enrolled as controls.
Thalassemia patients enrolled in the current work
were on regular red cell transfusion regimen, 33 cases
were transfused every 4 weeks, while 22 and 10 cases
were transfused every 3 weeks and 2 weeks respectively
to keep their target haemoglobin [16].
All subjects in our study were questioned for known risk
factors for atherosclerosis, patients with history of smok-
ing, hepatic, renal or cardiac diseases were excluded. Also
those with diabetes mellitus or other endocrinopathies,
other hemoglobinopathies, familial hypercholesterolemia
or premature atherosclerosis in their families were also
excluded.
The study protocol was approved by the research and
ethical committee of Faculty of Medicine, Zagazig
University and written informed consent was taken from
parents or guardian of each participant.
Methods
All eligible children (patients and controls) were
subjected to; history taking with special emphasis on
demographic characteristics, disease duration, frequency of
transfusions, iron chelation regimen including type, dose,
duration and compliance. Thorough clinical examination
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including anthropometric measures and all system
evaluation were performed. Routine laboratory investiga-
tions for follow up thalassemia patients that included;
complete blood count, liver function tests, renal function
tests, serum ferritin, C-reactive proteins and hepatitis
markers were taken.
Specific tests for evaluation of atherosclerosis were
performed and included 12-h fasting lipid profile, serum
Osteoprotegerin (OPG) assay, and carotid artery intima-
media thickness. All blood sampling for patients were
performed at the day before red blood cell transfusion.
Lipid profile was taken after at least 12 h overnight
fasting, it was performed by endpoint method (colorimet-
ric method) and included; total serum cholesterol, high
density lipoprotein- cholesterol (HDL-C), serum triglycer-
ide (TG). Low density lipoprotein –cholesterol (LDL-C)
was estimated using Friedewald and Levyformula [17] by
calculation of (TG)-(TG/5)-(HDL-C). Atherogenic index
of plasma (AIP) is the ratio calculated as log (TG/HDL-
C). Serum samples for assay of OPG were separated and
stored at −20 C0. It was performed using Human OPG
ELISA Kit, Boster Biological Technology Co., Ltd. USA.
Carotid artery intima-media thickness (CAIMT) mea-
surements were performed for all participants by the same
experienced vascular radiologist who was blinded to the
clinical and laboratory details of the examined children.
Duplex ultrasound B-mode and color-coded duplex son-
ography were performed using a (GE LOGIC P5) ultra-
sound system with a 12.0 MHz linear array transducer.
Statistical analysis
All data were analyzed using SPSS 22.0 for windows (SPSS
Inc., Chicago, IL USA) and MedCal 13 for windows
(MedCal software bvba). Continuous variables were
expressed as mean ± SD while categorical variables were
expressed as number (percentages). Continuous variables
were checked for normality using Shapiro-Wilk test. Inde-
pendent student-t test was used to compare the normally
distributed variables while Mann–Whitney U (MW) test
was used to compare non-normally distributed variables
between two groups. Categorical variables were compared
by using Chi-square test (X2). Pearson’ correlation coeffi-
cient and Spearman’ rank correlation were used to assess
relationship between normally distributed and non-
normally distributed variables respectively. All tests are two
sided, and p < 0.05 was considered statistically significant.
Results
Sixty-five B-thalassemia major (B-TM) patients were re-
cruited in the current work, their mean age was 9.5 ±
3.7 years (ranged 5–18 years), and 57% of them were
males. All of them were transfusion-dependent with ill-
ness duration ranged from 4–17 years (mean 8.5 ±
3.8 years), almost half of them (50.7%) were on every
4 weeks transfusion regimen, 34% were on 3 weekly regi-
men while for the remaining 15.3% cases every two weeks
transfusion was needed to keep target hemoglobin. Deferi-
prone was used as iron chelation in 49% of them, 45%
used Deferasirox while the remaining 6% were still using
desferrioxamine as iron chelation therapy.
Results of B-TM patients’ clinical evaluations, routine
and specific laboratory investigations were compared with
those of fifty, age and gender, matched healthy children.
Apart from height, no significant difference could be
detected atdemographic or anthropometric measures be-
tween patients and controls as shown in Table 1. On the
contrary, significant differences were documented when
results of complete blood count and routine chemical ana-
lysis were evaluated as displayed in Table 2. B-TM patients
had significantly higher white blood cell count and plate-
lets but much lower hemoglobin concentration than
healthy comparisons. Almost thirty fold rise in serum
ferritin was reported (2490 ± 1579 ng/dl vs 83 ± 32 ng/dl,
p = 0.001) for cases than controls. Significant rise in
hepatic enzymes, total bilirubin and C-reactive protein
were also revealed in patients group than healthy peers.
Significantly higher serum triglyceride (128 ± 20 vs 101 ±
7 mg/dl, p = 0.009) and calculated atherogenic index of
plasma (0.45 ± 0.12 vs 0.22 ± 0.04, p = 0.001) were recorded
in patients than comparisons. On the contrary, total serum








Mean ± SD 9.5 ± 3.7 10.4 ± 3.7 MW= −0.348 0.729
Range 5 – 18 5 – 18
Sex No (%)
Male 37 (57%) 34 (68%) χ2 = 1.048 0.306
Female 28 (43%) 16 (32%)
Residence No (%)
Urban 25 (38.5%) 23 (46%) χ2 = 0.062 0.803
Rural 40 (61.5%) 27 (54%)
Weight (Kg)
Mean ± SD 27.5 ± 8.1 33.8 ± 10.8 t = −1.76 0.085
Range 14 – 45 19 – 60
Height (cm)
Mean ± SD 114.7 ± 21.8 132 ± 22 t = −2.15 0.038
Range 95 – 155 100 – 168
BMI (Kg/m2)
Mean ± SD 18.1 ± 2.2 21.5 ± 6.9 MW= 1.45 0.191
Range 16 – 21 16 – 33
MW Mann Whitney U test, χ2 Chi-square test, p < 0.05 is significant,
t independent Student t-test, BMI Body mass index
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cholesterol (116 ± 16 vs 143 ± 5, p < 0.001), low density
lipoprotein-cholesterol (LDL-C) (44 ± 9 vs 73 ± 6, p < 0.001)
and high density lipoprotein cholesterol (HDL-C) (39 ± 2 vs
61 ± 5, p < 0.001), were significantly lowered in patients ver-
sus normal controls as displayed in Fig. 1.
ELISA assay of serum Osteoprotegerin (OPG) revealed
significantly higher levels for thalassemia patients than
matched healthy controls (427 ± 102 vs 324 ± 126 pg/ml,
p = 0.02) as expressed in Fig. 2. Of particular interest is
the obvious positive correlation between OPG levels and
CAIMT of both sides (Rt r 0.549, p = 0.001 &Lt r 0.479,
p = 0.001) and also with serum triglycerides (r 0.374, p =
0.03) as shown among other parameter in Table 3.
Duplex ultrasonographic Carotid arteries intima media
thickness (CAIMT) of both side were significantly increased
for patients (Rt 0.62 ± 0.2 vs. 0.29 ± 0.07 mm, p= 0.001 & Lt
0.66 ± 0.17 vs 0.29 ± 0.05 mm, p= 0.001) when compared
with healthy controls as described in Table 4. These
findings have pointed to the high frequency of
atherosclerosis among thalassemia group. Documented
positive correlation of CAIMT with serum triglyceride
andatherogenic index of plasma have supported the
previous data. Significant positive relationship between
CAIMT and S. Osteoprotegerin (OPG) was also ascer-
tained in our thalassemia patients as shown in Table 5.
Discussion
In the current study we tested the hypothesis that
chronic hemolytic anemia may lead to vascular damage
and premature atherosclerosis in B-TM patients. Our re-
sults documented significantly higher carotid artery
intima-media thickness (CAIMT) of both sides among
B-TM patients than matched controls (p < 0.001), a find-
ing that provided evidence to the real risk of atheroscler-
osis for these patients.
As endothelial dysfunction and increased arterial thick-
ness are important risk factors for the development of ath-
erosclerosis [18], several studies have reported the
measurement of arterial intima-media thickness as a good
determinant of subclinical atherosclerosis [19–21]. In-
creased CAIMT have been described as a mirror of ath-
erosclerotic burden, and a predictor of subsequent events
including myocardial infarction and stroke [8, 19]. Because
of its quantitative value, it has been used more and more
in clinical trials [8], and noticeably trusted in detecting
pre-clinical (asymptomatic) atherosclerosis in clinical set-
ting [7]. Depending on the aforementioned advantages of
this modality, our team and other researchers [19–21]
have used this technique as a gold standard for early de-
tection of atherosclerosis. Few studies have been per-
formed on adults and adolescent patients with B-TM
patients and showed significant increase in their CAIMT
[21, 22] but to the best of our knowledge this work is the
first to evaluate premature atherosclerosis in Egyptian B-
TM children with this modality.
There are limited data concerning atherosclerosis risks in
these patients, we evaluated clinical and laboratory parame-
ters that may be relevant to vascular injury and atherogen-
sis. Clinical characteristics didn’t show any difference from








Mean ± SD 11.3 ± 4.6 7.3 ± 1.8 MW= 2.5 0.013
Range 9 – 18.3 5 – 9
Hb (gm/dl)
Mean ± SD 6.8 ± 0.9 12.6 ± 0.7 t = −17.5 <0.001
Range 5 – 8.3 11.8 –14.2
PLT (×103/mm3)
Mean ± SD 478.4 ± 279.4 276 ± 77.6 MW= 2.2 0.030
Range 136 – 1428 170 – 405
SGOT (IU/L)
Mean ± SD 52.3 ± 39.4 30.4 ± 6.8 MW= 2.74 0.020
Range 9 – 160 20 – 40
SGPT (IU/L)
Mean ± SD 46.4 ± 38.4 29.7 ± 6.8 MW= 2.36 0.020
Range 8 – 155 19 – 38
Total bilirubin (mg/dl)
Mean ± SD 1.4 ± 0.6 0.6 ± 0.2 MW= 3.84 0.001
Range 0.6 – 2.8 0.4 – 0.9
Direct bilirubin
Mean ± SD 0.2 ± 0.1 0.2 ± 0.1 MW= −0.147 0.885
Range 0.1 – 0.5 0.1 – 0.4
Total Proteins (gm/dl)
Mean ± SD 6.1 ± 1.3 6.8 ± 0.8 t = −1.462 0.154
Range 4.5 – 8 5.2 – 8
Urea (mg/dl)
Mean ± SD 29.6 ± 6.9 27.5 ± 5.6 MW= −0.167 0.847
Range 21 – 41 15 – 37
Creatinine (mg/dl)
Mean ± SD 0.5 ± 0.3 0.4 ± 0.2 t = 0.341 0.766
Range 0.3 – 0.8 0.2 – 0.7
CRP
Mean ± SD 5.7 ± 5.7 0.9 ± 0.9 MW= 2.6 0.012
Range 1 – 21 0 – 2
S. ferritin (ng/dl)
Mean ± SD 2490 ± 1579 83 ± 32 MW= 4.7 <0.001
Range 653 – 8406 30 – 127
MW Mann Whitney U test, SGOT Aspartate transaminase, t independent
Student t-test, SGPT Alanine transaminase, p < 0.05 is significant, CRP
C- reactive protein
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Fig. 1 Lipid profile distribution of the studied groups: bar represent mean; Y-error bar represent 95% confidence interval of mean
Fig. 2 Serum Osteoprotegerin (pg/ml) distribution of the studied groups: bar represent mean; Y-error bar represent 95% confidence interval of mean
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controls, or significant correlations with CAIMT. However,
results of the hematologic and biochemical investigations of
our B-TM patients displayed very peculiar metabolic model
with; significant anemia, sky high increase in serum ferritin,
and dyslipidemia which presented as high triglyceride and
atherogenic index of plasma (AIP) but associated with low
total cholesterol, LDL-C and HDL-C in patients as com-
pared with comparisons.
Hemolytic anemia might be a predisposing factor for
atherosclerosis by several mechanisms. First, erythrocyte
release arginase enzyme during hemolysis coupled with
the liberation of cell –free hemoglobin [23] contribute to
dysregulated arginine metabolism with low arginine/orni-
thine ratio. These metabolic derangements limit the avail-
ability of arginine to nitric oxide synthase and lead to
vascular dysfunction by disturbing the bioavailability of
nitric oxide (NO) [24, 25]. Second, anemia was described
as risk factor of hypertriglyceridemia due to its negative
impact on extra-hepatic lipolytic activity [26].
Significantly high S. ferritin was found among B-TM pa-
tients in our series, this finding was in agreement with
many previous researchers [27, 28]. Poor compliance to
iron chelation was obvious among our patient (51%), rep-
resented an important and probably correctable cause of
iron overload. High iron burden may increase patient’s
risk for atherosclerosis by excess free radicle production
[29, 30]. Moreover, Mansi and Aburjai documented posi-
tive correlation between S. ferritin and triglyceride level
“an important predictor of atherosclerosis” [31]. Against
our expectation, no significant correlation could be de-
tected between CAIMT and S. ferritin, and similar result
was previously documented by Tantawy and his colleague
[21]. This data suggested that non-transferrin bound iron
accumulation at cellular level with subsequent macro-
phage activation may be the triggering for development of
atherosclerosis rather than high serum ferritin level [32].
Children with beta thalassemia are at increased risk of de-
veloping premature atherosclerosis because of dyslipidemia
[21]. Lipid profiles have been described by several investiga-
tors but with conflicting results [26, 33–36]. Most of them
including our team have shared common findings of low-
ered total cholesterol, LDL-C, HDL-C [27, 34–39]. Values
from our B-TM patients and many other researchers showed
elevated triglyceride levels (TG) [33, 34, 36–38], while others
described TG levels as being not- significantly different from
controls [35, 39]. CAIMT in the present study was positively
correlated with S. TG and atherogenic index of plasma.
Table 3 Correlations between Osteoprotegerin (OPG) and
different parameters in the patients
Parameters Osteoprotegerin (OPG)
r p-value
Age - 0.082 0.649
Duration of disease (years) - 0.063 0.729
Body mass index (BMI) +0.331 0.060
Serum ferritin - 0.086 0.633
Serum cholesterol - 0.205 0.253
High density lipoproteins (HDL-C) - 0.263 0.140
Low density lipoproteins (LDL-C) - 0.318a 0.071
Triglycerides (TG) +0.374 0.032
Atherogenic index of plasma (AIP) +0.263 0.140
C-reactive protein (CRP) - 0.173 0.336
Right carotid artery intima media
thickness (Rt. CAIMT)
+0.549 0.001
Left carotid artery intima media
thickness (Lt. CAIMT)
+0.479 0.001
Aspartate transaminase (AST) - 0.170 0.344
Alanine transaminase (ALT) - 0.294 0.097
r correlation coefficient
aPearson’s correleation coefficient
p < 0.05 is significant
Table 4 Radiological parameters of the studied group
CAMIT (mm) Patients (N = 65) Controls (N = 50) MW p-value
Right carotid artery (IMT)
Mean ± SD 0.62 ± 0.20 0.29 ± 0.07 5.142 <0.001
Range 0.4 – 1.1 0.2 – 0.4
Left carotid artery (IMT)
Mean ± SD 0.66 ± 0.17 0.29 ± 0.05 6.609 <0.001
Range 0.4 – 1.2 0.2 – 0.4
MW Mann Whitney U test, CAMIT Carotid artery intima media thickness,
p < 0.05 is significant, mm millimeter
Table 5 Correlation between carotid artery intima media
thickness and different parameters of the patients
Parameters Rt. CAIMT Lt CAIMT
r p r p
Age +0.172 0.340 +0.083 0.646
Disease duration (years) +0.195 O.276 +0.125 0.487
BMI +0.123 0.494 +0.143 0.427
Serum ferritin +0.200 0.264 +0.059 0.744
Serum cholesterol −0.086 0.633 −0.087 0.631
TG +0.275 0.121 +0.453 0.008
HDL-C +0.164 0.361 +0.048 0.790
LDL-C −0.235 0.188 −0.225 0.207
AIP +0.155 0.388 +0.446 0.009
CRP −0.115 0.525 −0.129 0.473
OPG +0.411 0.018 +0.390 0.025
SGOT +0.387 0.026 +0.003 0.985
SGPT +0.307 0.082 +0.022 0.903
CAMIT carotid artery intima media thickness, BMI Body mass index, r
Spearman’s rank correleation coefficient, TG Triglycerides, p < 0.05 is significant,
AIP Atherogenic index of plasma, OPG osteoprotegerin, SGOT Aspartate
transaminase, SGPT Alanine transaminase, CRP C-reactive protein, HDL-C High
density lipoproteins cholesterol, LDL-C Low density lipoprote
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Dyslipidemia in thalassemia patients has been previously
explained by several researchers who speculated different
pathophysiologic pathways; plasma dilution because of
anemia, accelerated erythropoiesis with excess cholesterol
uptake by macrophages and histocytes of the reticuloen-
dothelial system, defective liver synthetic function because
of iron overload, macrophage activation with cytokine re-
lease and hormonal disturbance [33, 40, 41] while reduced
extra-hepatic lipolytic activity might be responsible for the
increased TG in B-TM patients [33].
It was surprising that our B-TM patients had early ath-
erosclerosis despite low LDL-C, this observation is pos-
sibly due to oxidative change of LDL-C to “atherogenic
LDL” by unbalanced oxidant- antioxidant milieu in thal-
assemia patients [42–45].
Atherogenic index of plasma (AIP) is a marker of
atherogenicity since it is related directly to atheroscler-
osis; it is calculated as log (TG/HDL-C). Hypertriglyc-
eridemia will increase the activity of hepatic lipase which
results in HDL-C degradation with subsequent increased
risk of coronary atherosclerosis [46]. In the present
work, there was significant increase in AIP ratio for B-
TM patients than for the healthy controls and also, it
displayed positive correlation with CAIMT. These find-
ing was in agreement with those by Najajou et al. and
Daniel et al. who reported high predictive value of AIP
for development of atherosclerosis [47, 48].
Rt. CAIMT showed significant correlation with SGOT
(AST) but not with other liver enzyme, these findings might
point to hemolysis in triggering atherosclerosis in our pa-
tients as hemolysis is the main source of elevated AST [49].
In the current study we had the chance to ascertain
that Osteoprotegerin (OPG) was significantly raised in
patients as compared with comparisons (P < 0.001), and
to document the positive correlation that displayed be-
tween OPG, CIMT, and TG. Elevated OPG level was
suggested; as a marker of arterial damage [50], as pre-
dictor of coronary artery diseases, [51] and overall car-
diovascular morbidity and mortality [52], but as far as
our knowledge our team was the first to investigate the
relationship between atherosclerosis as expressed by
CIMT and OPG in B-TM patients.
Results from two large cohort studies for the validity of
OPG assay as a predictor of atherosclerosis and coronary
artery diseases were supporting for its clinical application
in predicting atherosclerosis in asymptomatic high-risk
individuals [53], [54]. Positive correlation between OPG
and CIMT observed among our B-TM patientshighlighted
its importance as promising biomarker of subclinical
atherosclerosis detection.
Conclusions
Premature subclinical atherosclerosis was documented
among Egyptian beta thalassemia major patients by
evaluating their carotid artery intima media thickness
(CAIMT). It was correlated well with dyslipidemia and
serum osteoprotogrin, a finding that highlighted the pos-
sible validity of OPG assay as an early predictor of athero-
sclerosis in thalassemia children. However, multicenter
wide scale research is warranted to evaluate OPG assay cut-
off value, its sensitivity and specificity as reliable biomarker
for diagnosis of atherosclerosis.
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